Kenan Turnacioglu
General Partner @ Catalio Capital Management
New York, United States
Kenan Turnacioglu is a General Partner & Member of the Investment Committee at Catalio Capital Management.He is also the Chairman of PaigeAI, a machine learning pathology company spun out of Memorial Sloan Kettering. In 2011, Kenan co-founded PointState Capital, LP and managed the portfolios and investment teams in Healthcare and Consumersectors, before departing in 2018. From 2001 to 2010, he worked at Duquesne Capital Management, LLC managing Healthcare investments. While at these positions he also served on the Boards of StemCentrx (2013-2016), Agensys (2004-2007), and NYU Langone Cancer Center (2010-2015). From 1998-2000, he worked at Credit Suisse as an analyst on the biotech team.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Kenan Turnacioglu invests in
Stages Kenan Turnacioglu invests in
Countries Kenan Turnacioglu invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Artificial Intelligence 4 (67%)
- Medical 2 (33%)
- Software 2 (33%)
- Biopharma 2 (33%)
- Health Care 2 (33%)
Stage
- Series A 3 (50%)
- Series B 2 (33%)
- Seed 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Network Bio is a clinical and molecular data library enabling precision medicine approaches for common human diseases. Its platform delivers a centralized repository for clinical and molecular data that allows researchers to identify patterns and correlations that can be used to develop new treatments and diagnostic tools. | $17M / Seed / Feb 27, 2025 | ||
| Massive Bio, is an Artificial Intelligence (AI) powered platform that connects cancer patients and their treating oncologists to clinical trials while enabling pharmaceutical companies to get access to patients, mostly in community practices, and their information to speed up drug development. Massive Bio combines technology, services and oncologysub-specialist expertise to maximize trial enrollment. Massive Bio is the first company that attacks controlling patient enrollment value chain; Massive Bio does patient identification through direct direct and indirect patient acquisition channels, pre-screening through virtual site, Just-In-Time (JIT) site activation and further analyzes real world data for drug discovery. One of the major differentiating point of Massive Bio is that the Company tackles “last mile” issues for trial enrollment to eliminate site and/or financial considerations of patients. Massive Bio is the go to partner for pharmaceutical companies and CROs to get the right patient at the right time. | $16.5M / Series A / Jun 02, 2022 | ||
| Immunai is a biotech company that combines single-cell genomics with ML algorithms to enable high-resolution profiling of the immune system.Immunai's mission is to map the entire immune system and its functions using single-cell genomics and machine learning. Immunai leverages single-cell technologies to profile cells from a blood sample,and uses machine-learning algorithms (powered by its proprietary database) to map the hundreds of cell types and their states to create an immune profile. They work on biomarker discovery and insights that identify how a cell responds to its changing environment.The company is located in New York City, San Francisco, and Tel Aviv, Israel. | $60M / Series A / Feb 11, 2021 | ||
| Sirona Medical is revolutionizing radiology by delivering a cloud-native platform that unifies the worklist, viewer, reporter, archive, and AI into a single, intuitive workspace. Designed specifically for radiologists, Sirona’s platform simplifies complex workflows, enhances productivity, and empowers practitioners to work as fast as they think.Founded in San Francisco, CA, Sirona combines deep expertise in the practice and business of radiology to create purpose-built solutions that address the evolving needs of the field. By streamlining radiology workflows and integrating cutting-edge AI, Sirona enables radiologists to deliver better, faster, and more efficient care. | $9M / Series A / Aug 28, 2020 | ||
| Paige was founded in 2017 by Thomas Fuchs, Dr.Sc., and colleagues from Memorial Sloan Kettering Cancer Center. The Company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of diagnostic devices positioned to drive the future of pathology,Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s lightweight platform was purpose-built with pathologists to offer an intuitive user experience, minimize IT burden and costs while ensuring patient safety and data privacy. Paige’s products deliver insights to pathologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA breakthrough designation for computational pathology products. | $45M / Series B / Dec 18, 2019 | ||
| See all 6 investments → | |||
Co-Investors
Catalio Capital Management is a venture capital firm that invests in breakthrough biomedical technology companies.
Catalio Capital Management Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ben Snedeker
Partner and Co-Head Public Equities
|
|||
George Petrocheilos
Co-Founder & Managing Partner
|
|||
Isaac Ro
Partner
|
|||
Jacob Vogelstein
Co-Founder and Managing Partner
|
|||
|
Kenan Turnacioglu
General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Kenan Turnacioglu invest in?
Kenan Turnacioglu invests primarily in Artificial Intelligence, Medical and Software startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Kenan Turnacioglu?
Public channels for Kenan Turnacioglu include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Kenan Turnacioglu last invest?
The most recent investment recorded for Kenan Turnacioglu closed in Feb 2025. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
